drug_type
RELEVANT_DRUG
intervention_type
Antibody–drug conjugate (ADC)
drug_description
Anti-HER2 antibody–drug conjugate delivering MMAE (microtubule inhibitor) to HER2-overexpressing tumor cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
disitamab vedotin
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Disitamab vedotin is an anti-HER2 monoclonal antibody conjugated to the microtubule inhibitor MMAE. It binds HER2 on tumor cells, is internalized, and releases MMAE via a protease-cleavable linker in lysosomes, leading to microtubule disruption, G2/M cell-cycle arrest, and apoptotic cell death; the antibody component may also contribute to antitumor activity via Fc-mediated effector functions.
drug_name
Disitamab vedotin (RC48)
nct_id_drug_ref
NCT06385873